![Tabrecta (Capmatinib) Approved for Patients with Metastatic NSCLC and MET Exon 14 Skipping Mutation | Oncology Practice Management Tabrecta (Capmatinib) Approved for Patients with Metastatic NSCLC and MET Exon 14 Skipping Mutation | Oncology Practice Management](https://oncpracticemanagement.com/images/Tables-Figures/2021/04/OPM-2021-04-JCode-Pg18-Tbl-Capmatinib-Efficacy.png)
Tabrecta (Capmatinib) Approved for Patients with Metastatic NSCLC and MET Exon 14 Skipping Mutation | Oncology Practice Management
Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from a
![Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts - Bang - 2020 - Cancer Science - Wiley Online Library Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts - Bang - 2020 - Cancer Science - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/2e5c3034-3a87-4d7f-94f3-a630319f0b56/cas14254-fig-0001-m.jpg)
Phase 1 study of capmatinib in MET‐positive solid tumor patients: Dose escalation and expansion of selected cohorts - Bang - 2020 - Cancer Science - Wiley Online Library
![Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a two-drug cocktail in patients with MET-dysregulated advanced solid tumors: A phase I, multicenter, open-label, single-sequence drug-drug interaction study - Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a two-drug cocktail in patients with MET-dysregulated advanced solid tumors: A phase I, multicenter, open-label, single-sequence drug-drug interaction study -](https://authorea.com/users/344743/articles/471149-effect-of-capmatinib-on-the-pharmacokinetics-of-digoxin-and-rosuvastatin-administered-as-a-two-drug-cocktail-in-patients-with-met-dysregulated-advanced-solid-tumors-a-phase-i-multicenter-open-label-single-sequence-drug-drug-interaction-study/master/file/figures/Figure_1/Figure_1.png?1606780175)
Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a two-drug cocktail in patients with MET-dysregulated advanced solid tumors: A phase I, multicenter, open-label, single-sequence drug-drug interaction study -
![These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA. TABRECTA® (capmatinib) tablets, for oral use Initial U.S. Approval: 2020 These highlights do not include all the information needed to use TABRECTA safely and effectively. See full prescribing information for TABRECTA. TABRECTA® (capmatinib) tablets, for oral use Initial U.S. Approval: 2020](https://dailymed.nlm.nih.gov/dailymed/image.cfm?name=inc280-03.jpg&id=703247)